{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:30Z","timestamp":1790357370583,"version":"4.1.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"\n Importance<\/jats:title>\n The antifungal medication voriconazole is used to prevent and treat aspergillosis, a major cause of mortality among recipients of lung transplants (hereinafter referred to as lung recipients). Small studies suggest that voriconazole increases risk of cutaneous squamous cell carcinoma (SCC).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine associations of voriconazole and other antifungal medications with risk of keratinocyte carcinomas (SCC and cutaneous basal cell carcinoma [BCC]) in lung recipients.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study included non-Hispanic white patients (n\u2009=\u20099599) who underwent lung transplant in the United States from January 1, 2007, to December 31, 2016, identified through the national Scientific Registry of Transplant Recipients with data linkable to pharmacy claims. Data were analyzed from March 1, 2018, to February 13, 2019.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Antifungal medication use, including voriconazole, itraconazole, posaconazole, and other antifungals, was ascertained from pharmacy claims and treated as a time-varying exposure (assessed every 30 days). Cumulative antifungal exposure was calculated as the total number of exposed months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were the first SCC or BCC reported to the transplant registry by transplant centers. Follow-up began at transplant and ended at SCC or BCC diagnosis, transplant failure or retransplant, death, loss to follow-up, or December 31, 2016. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (AHRs) for each antifungal medication.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 9793 lung transplants in 9599 recipients included in the analysis, median age at transplant was 59 (interquartile range [IQR], 48-65) years, 5824 (59.5%) were male, and 5721 (58.4%) reported ever smoking. During a median follow-up of 3.0 (IQR, 1.4-5.0) years after transplant, 1031 SCCs (incidence, 322 per 10\u202f000 person-years) and 347 BCCs (incidence, 101 per 10\u202f000 person-years) were reported. Compared with lung recipients with no observed voriconazole use, those with 1 to 3 months of voriconazole use experienced increased AHR for SCC of 1.09 (95% CI, 0.90-1.31); 4 to 7 months, 1.42 (95% CI, 1.16-1.73); 8 to 15 months, 2.04 (95% CI, 1.67-2.50); and more than 15 months, 3.05 (95% CI, 2.37-3.91). Ever itraconazole exposure was associated with increased SCC risk (AHR, 1.20; 95% CI, 1.00-1.45). For BCC, risk was not associated with voriconazole use but was increased with itraconazole use (AHR, 1.74; 95% CI, 1.27-2.37) or posaconazole use (AHR, 1.55; 95% CI, 1.00-2.41).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, voriconazole use was associated with increased SCC risk among lung recipients, especially after prolonged exposure. Further research evaluating the risk-benefit ratio of shorter courses or alternative medications in transplant recipients at high risk for SCC should be considered.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2020.1141","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T22:03:59Z","timestamp":1589407439000},"page":"772","source":"Crossref","is-referenced-by-count":40,"title":["Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States"],"prefix":"10.1001","volume":"156","author":[{"given":"Monica E.","family":"D\u2019Arcy","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna R.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Hess","sequence":"additional","affiliation":[{"name":"The Wharton School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Cahoon","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Arron","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Brownell","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Cowen","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Israni","sequence":"additional","affiliation":[{"name":"Kidney Transplant Program, Hennepin Healthcare, University of Minnesota, Minneapolis"},{"name":"Scientific Registry of Transplant Recipients, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Triplette","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Yanik","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Engels","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"doi200023r3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients.","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"9581","key":"doi200023r4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"doi200023r5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/ijc.27765","article-title":"Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008\u2014a Swedish population-based study.","volume":"132","author":"Krynitz","year":"2013","journal-title":"Int J Cancer"},{"issue":"15","key":"doi200023r6","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-16-3291","article-title":"Risk of second malignancies in solid organ transplant recipients who develop keratinocyte cancers.","volume":"77","author":"Zamoiski","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"doi200023r7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jaad.2012.09.030","article-title":"Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation.","volume":"68","author":"Gogia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"doi200023r8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation.","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"doi200023r9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jnci\/djs529","article-title":"HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer.","volume":"105","author":"Silverberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"doi200023r10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/tid.12362","article-title":"Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience.","volume":"17","author":"Vazquez","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"doi200023r11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2014a world-wide survey.","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"doi200023r12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/tid.12337","article-title":"Practice variation in aspergillus prophylaxis and treatment among lung transplant centers: a national survey.","volume":"17","author":"He","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"doi200023r13","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"issue":"7","key":"doi200023r14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/cid\/cit940","article-title":"Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients.","volume":"58","author":"Williams","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"doi200023r15","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1086\/511685","article-title":"Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy.","volume":"44","author":"McCarthy","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"doi200023r16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole.","volume":"62","author":"Cowen","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi200023r17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/pbc.24897","article-title":"Phototoxic dermatoses in pediatric BMT patients receiving voriconazole.","volume":"61","author":"Goyal","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"doi200023r18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3121\/cmr.2008.806","article-title":"Voriconazole-induced photosensitivity.","volume":"6","author":"Malani","year":"2008","journal-title":"Clin Med Res"},{"issue":"1","key":"doi200023r19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajt.13431","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients.","volume":"16","author":"Mansh","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"doi200023r20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/tri.12865","article-title":"Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation.","volume":"30","author":"Kolaitis","year":"2017","journal-title":"Transpl Int"},{"issue":"7","key":"doi200023r21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.healun.2012.02.033","article-title":"High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.","volume":"31","author":"Singer","year":"2012","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"doi200023r22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.healun.2012.05.003","article-title":"Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.","volume":"31","author":"Feist","year":"2012","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"doi200023r23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/tid.12063","article-title":"Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart\/lung transplant patients.","volume":"15","author":"McLaughlin","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"doi200023r24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.healun.2010.05.022","article-title":"Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients.","volume":"29","author":"Vadnerkar","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"doi200023r25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/ajt.14500","article-title":"Voriconazole and squamous cell carcinoma after lung transplantation: a multicenter study.","volume":"18","author":"Hamandi","year":"2018","journal-title":"Am J Transplant"},{"issue":"2","key":"doi200023r26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaad.2018.08.010","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: a systematic review and meta-analysis.","volume":"80","author":"Tang","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi200023r27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.09.010","article-title":"Incidence and risk factors for skin cancer following lung transplantation.","volume":"72","author":"Rashtak","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi200023r28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2017.09.003","article-title":"Validity of skin cancer malignancy reporting to the Organ Procurement Transplant Network: a cohort study.","volume":"78","author":"Garrett","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi200023r29","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/ijc.31735","article-title":"Risk of Kaposi sarcoma after solid organ transplantation in the United States.","volume":"143","author":"Cahoon","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"doi200023r30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjd.14838","article-title":"Voriconazole exposure regulates distinct cell-cycle and terminal differentiation pathways in primary human keratinocytes.","volume":"176","author":"Mansh","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200023r31","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1038\/s41598-018-23439-7","article-title":"Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation.","volume":"8","author":"Ikeya","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"doi200023r32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"doi200023r33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamadermatol.2015.5473","article-title":"Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma.","volume":"152","author":"Ally","year":"2016","journal-title":"JAMA Dermatol"},{"key":"doi200023r34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejmech.2018.11.056","article-title":"Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.","volume":"163","author":"Teske","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"1","key":"doi200023r35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2001.19.1.231","article-title":"Relation between smoking and skin cancer.","volume":"19","author":"Wensveen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"doi200023r36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"doi200023r1","unstructured":"US Department of Health and Human Services. Organ Procurement and Transplantation Network. 2018. Accessed February 4, 2018. https:\/\/optn.transplant.hrsa.gov"},{"key":"doi200023r2","unstructured":"Health Resources and Services Administration. OPTN\/SRTR 2017 annual data report: lung. 2019. Accessed May 18, 2019. https:\/\/srtr.transplant.hrsa.gov\/annual_reports\/2017\/Lung.aspx"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2765342\/jamadermatology_darcy_2020_oi_200023_1740435804.64767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:00:39Z","timestamp":1740567639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2765342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.1141","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737947238.793578255","asserted-by":"object"}]},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}